search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Reimbursement for smoking cessation treatment.


- candidate number0
- NTR NumberNTR104
- ISRCTNISRCTN55212198
- Date ISRCTN created12-sep-2005
- date ISRCTN requested18-aug-2005
- Date Registered NTR20-jul-2005
- Secondary IDsSTIVORO and the Dutch Asthma Foundation 3.4.03.28 
- Public TitleReimbursement for smoking cessation treatment.
- Scientific TitleThe (cost)-effectiveness of reimbursement for smoking cessation treatment.
- ACRONYMN/A
- hypothesisN/A
- Healt Condition(s) or Problem(s) studiedSmoking cessation
- Inclusion criteriaWe included smokers of at least 18 years old and healthcare insured by health insurance company "De Friesland Zorgverzekeraar". Participants did not have to be motivated to quit smoking.
- Exclusion criteriaOnly one smoker per household was allowed to participate.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingSingle
- controlActive
- groupParallel
- Type[default]
- Studytypeintervention
- planned startdate 1-mei-2002
- planned closingdate1-mei-2003
- Target number of participants1266
- InterventionsFor a period of 6 months, smokers in the intervention group had the opportunity to apply for reimbursement for SCT. They received a leaflet with a description of the SCTs for which reimbursement was available, and information on how to receive the reimbursement. Smokers in the intervention group could receive full reimbursement for pharmacological treatment (bupropion and NRT (chewing gum, patch, tablet, sublingual tablet and inhaler)), behavioural counselling (written advice, telephone or face to face counselling) or a combination. To receive reimbursement, they had to send the receipt and two statements of personal contact with a health care professional (general practitioner, general practice nurse, physician, psychologist or health community worker) to the health insurance company. Before the study started, all the health care professionals in the study region were informed about the study. No limit was set on the number of applications for reimbursement.
In the control, no reimbursement or information about smoking cessation treatment was offered.
- Primary outcomeThe primary outcome measure of the reimbursement study was continuous abstinence from smoking. Continuous abstinence was defined as not having smoked for at least seven days preceding the 6-month and 12-month questionnaire and not having relapsed between both questionnaires. After the 6-month and 12-month questionnaire, quitters were contacted to make an appointment for biochemical validation of their smoking status.
- Secondary outcomeSecondary outcomes were the use of smoking cessation treatment, the number of quit attempts that were undertaken, and the cost-effectiveness of reimbursement was assessed.
- Timepoints
- Trial web siteN/A
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESMSc. J. Kaper
- CONTACT for SCIENTIFIC QUERIESMSc. J. Kaper
- Sponsor/Initiator University Maastricht (UM), CAPHRI Research Institute
- Funding
(Source(s) of Monetary or Material Support)
Netherlands Asthma Foundation, STIVORO
- Publications1. Addiction. 2005 Jul;100(7):1012-20;
2. Pharmacoeconomics. 2006;24(5):453-64;
3. Addiction. 2006 Nov;101(11):1656-61.
- Brief summaryN/A
- Main changes (audit trail)
- RECORD17-aug-2005 - 4-jun-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl
  • Dit zijn de gegevens waarmee uw trial is aangemeld en geregistreerd in het Nederlands Trial Register